You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

 

Online download statistics by month:

Online download statistics by month: October 2020 to July 2025

AbstractFullPdf
Oct 2020868627
Nov 2020183186108
Dec 2020454453118
Jan 202114614654
Feb 2021838337
Mar 2021696943
Apr 2021949429
May 202113413442
Jun 202112612637
Jul 202113213229
Aug 2021494939
Sep 2021959545
Oct 202110710756
Nov 2021878964
Dec 2021858558
Jan 2022808251
Feb 2022899159
Mar 2022899165
Apr 2022767850
May 2022919364
Jun 2022868952
Jul 202210410572
Aug 2022929567
Sep 202210911189
Oct 202210715391
Nov 202216116160
Dec 2022808050
Jan 2023707033
Feb 202310310342
Mar 202311411470
Apr 2023757554
May 2023555538
Jun 2023525239
Jul 2023565634
Aug 2023464631
Sep 2023838352
Oct 2023525244
Nov 2023686831
Dec 2023727233
Jan 2024505118
Feb 2024515117
Mar 20244747174
Apr 2024656732
May 2024495419
Jun 2024646528
Jul 2024474919
Aug 2024464523
Sep 2024646436
Oct 20244747512
Nov 2024444521
Dec 2024767823
Jan 2025454530
Feb 2025525240
Mar 2025616141
Apr 2025696934
May 2025333519
Jun 2025434315
Jul 2025110
Total489449783158